Delcath Systems Inc
NASDAQ:DCTH
Intrinsic Value
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. [ Read More ]
The intrinsic value of one DCTH stock under the Base Case scenario is 17.363 USD. Compared to the current market price of 4.475 USD, Delcath Systems Inc is Undervalued by 74%.
Valuation Backtest
Delcath Systems Inc
Run backtest to discover the historical profit from buying and selling DCTH stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Delcath Systems Inc
Current Assets | 37.2m |
Cash & Short-Term Investments | 32.5m |
Receivables | 392k |
Other Current Assets | 4.3m |
Non-Current Assets | 1.5m |
PP&E | 1.5m |
Current Liabilities | 16.4m |
Accounts Payable | 1m |
Accrued Liabilities | 5.3m |
Other Current Liabilities | 10.2m |
Non-Current Liabilities | 6.4m |
Other Non-Current Liabilities | 6.4m |
Earnings Waterfall
Delcath Systems Inc
Revenue
|
2.1m
USD
|
Cost of Revenue
|
-635k
USD
|
Gross Profit
|
1.4m
USD
|
Operating Expenses
|
-39.6m
USD
|
Operating Income
|
-38.2m
USD
|
Other Expenses
|
-9.5m
USD
|
Net Income
|
-47.7m
USD
|
Free Cash Flow Analysis
Delcath Systems Inc
What is Free Cash Flow?
DCTH Profitability Score
Profitability Due Diligence
Delcath Systems Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Delcath Systems Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
DCTH Solvency Score
Solvency Due Diligence
Delcath Systems Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Delcath Systems Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DCTH Price Targets Summary
Delcath Systems Inc
According to Wall Street analysts, the average 1-year price target for DCTH is 18.768 USD with a low forecast of 13.13 USD and a high forecast of 23.1 USD.
Ownership
DCTH Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
DCTH Price
Delcath Systems Inc
Average Annual Return | -51.31% |
Standard Deviation of Annual Returns | 26.81% |
Max Drawdown | -98% |
Market Capitalization | 120.3m USD |
Shares Outstanding | 25 439 300 |
Percentage of Shares Shorted | 3.87% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 45 full-time employees. The company went IPO on 2000-10-19. The firm's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The firm's product administers concentrated regional chemotherapy to the liver.
Contact
IPO
Employees
Officers
The intrinsic value of one DCTH stock under the Base Case scenario is 17.363 USD.
Compared to the current market price of 4.475 USD, Delcath Systems Inc is Undervalued by 74%.